Taiho Oncology, Inc. announced today presentations at the 2025 ASCO Gastrointestinal Cancers Symposium (ASCO GI), to be held ...

Roche's Chugai Pharmaceutical is starting off its centennial year by spending some Swiss cheese. | Roche's Chugai Chugai ...

ASTX-295 is under clinical development by Taiho Pharmaceutical and currently in Phase II for Glioblastoma Multiforme (GBM).

ASTX-295 is under clinical development by Taiho Pharmaceutical and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 37% phase transition success ...

“We’re open for business,” said Taiho Oncology, Inc. CEO, Timothy Whitten. Alongside its growing pipeline of orally administered oncology drugs, the US subsidiary of Japan’s Taiho ...

Taiho Oncology. "When administered at home, HMAs such as ASTX030 and INQOVI may potentially reduce the toll of time toxicity many patients with cancer experience and may help them to manage this ...

Oho, making his debut in the highest makuuchi division, is a grandson of Taiho, the late yokozuna of the Showa Era (1926-1989), who dominated sumo in postwar Japan. Oho’s father is ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

PRINCETON, N.J., Dec. 9, 2024 /PRNewswire/ -- Taiho Oncology, Inc., presented results of two studies focused on oral therapies for patients with myelodysplastic syndromes (MDS) and MDS ...